← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sentien Biotechnologies, Inc.
Lexington, MA
$6,786,137
Total funding
5
Grants
Funding over time
peak $1.7M · FY2010–17$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,636,137 · 4
NSF$150,000 · 1
By mechanism
R44$5,571,820 · 2
R43$1,064,317 · 2
—$150,000 · 1
Investigators at Sentien Biotechnologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$1,016,886
R44 · FY2014 · DK
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$1,006,437
R44 · FY2015 · DK
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$962,626
R44 · FY2016 · DK
Stem Cell Bioreactor for Cardiac Care$800,030
R44 · FY2017 · HL
Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure$773,285
R44 · FY2012 · DK
Stem Cell Bioreactor for Cardiac Care$771,827
R44 · FY2016 · HL
Cellular Device for the Treatment of Acute Liver Failure$307,888
R43 · FY2012 · DK
A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur$286,679
R43 · FY2011 · DK
A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur$278,332
R43 · FY2010 · DK
Stem Cell Bioreactor for Cardiac Care$240,729
R44 · FY2015 · HL
Cellular Device for the Treatment of Acute Liver Failure$191,418
R43 · FY2013 · DK
SBIR Phase I: Assembly and Storage of Cell-Derived Drug Delivery Devices$150,000
· FY2010 · TIP